Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Larimar Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
LRMR
Nasdaq
8731
https://larimartx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Larimar Therapeutics Inc
Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results
- Mar 14th, 2024 9:32 pm
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
- Mar 14th, 2024 8:05 pm
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
- Mar 11th, 2024 8:05 pm
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
- Mar 6th, 2024 9:05 pm
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
- Feb 16th, 2024 9:20 pm
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
- Feb 14th, 2024 11:15 am
Larimar Therapeutics Announces Proposed Underwritten Public Offering
- Feb 13th, 2024 9:18 pm
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia
- Feb 12th, 2024 12:00 pm
With 45% ownership, Larimar Therapeutics, Inc. (NASDAQ:LRMR) has piqued the interest of hedge funds investors
- Dec 9th, 2023 12:29 pm
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
- Nov 14th, 2023 12:00 pm
Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference
- Nov 1st, 2023 8:05 pm
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
- Oct 3rd, 2023 8:05 pm
Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference
- Aug 31st, 2023 8:05 pm
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
- Aug 10th, 2023 11:00 am
Larimar Therapeutics Insiders Placed Bullish Bets Worth US$1.2m
- Aug 7th, 2023 1:22 pm
These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say Analysts
- Jul 25th, 2023 1:59 pm
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial
- Jul 25th, 2023 11:00 am
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
- Jul 17th, 2023 8:05 pm
Larimar Therapeutics Set to Join Russell 3000® Index
- Jun 21st, 2023 8:05 pm
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results
- May 15th, 2023 11:00 am
Scroll